baber/WOPTO huggingface dataset:
Patent NZ-548209-A (NZ)
Title: Methods and materials for assessing prostate cancer thearapies
Inventor: SAWYERS CHARLES L
IPC: C12Q1/68
Filed: 2004-12-16
Abstract: Disclosed is a method of examining the physiological effect of a compound on a mammalian prostate cancer cell in vitro and/or in a non-human animal, wherein said prostate cancer cell expresses an exogenous wild type androgen receptor polynucleotide that encodes an androgen receptor polypeptide or an androgen receptor polypeptide variant, such that the total levels of mRNA in the cell that encode the androgen receptor polypeptide or the androgen receptor polypeptide variant, or the total protein levels of the androgen receptor polypeptide or androgen receptor polypeptide variant, are at least two-fold higher than the endogenous level of androgen receptor, mRNA or polypeptide in a hormone-sensitive prostate cancer cell, said method comprising (a) contacting a compound to be tested with said prostate cancer cell expressing exogenous wild type androgen receptor polynucleotide to provide a treated prostate cancer cell; and (b) comparing one or more physiological characteristics of said treated prostate cancer cell with the same one or more characteristics of a control prostate cancer cell to which the compound has not been administered, wherein a difference in the one or more characteristics indicates that the compound has a physiological effect on the treated prostate cancer cell; wherein the growth of said mammalian prostate cancer cell is androgen-independent; and wherein said compound decreases the biological function of androgen receptors by decreasing androgen receptor DNA levels, androgen receptor mRNA levels, androgen receptor protein levels; and further wherein said compound inhibits the growth of hormone-refractory prostate cancer cells.
Patent NZ-555951-A (NZ)
Title: Hemiasterlin derivatives and uses thereof
Inventor: KOWALCZYK JAMES J
IPC: A61K38/08
Filed: 2003-03-21
Abstract: Disclosed is the use of a compound of formula I in the manufacture of a medicament for treating cancer or a pharmaceutically acceptable salt thereof; wherein X1 and X2 are each C(=O); and wherein the rest of the substituents are disclosed within the specification.
Patent NZ-555975-A (NZ)
Title: High-strength four-phase steel alloys
Inventor: KUSINSKI GRZEGORZ J
IPC: C22C38/18
Filed: 2005-11-29
Abstract: Disclosed is a process for manufacturing a high-strength, ductile, corrosion-resistant carbon steel, said process comprising: (a) heating an alloy composition to a temperature sufficiently high to form a starting microstructure comprising a substantially martensite-free austenite phase, said alloy composition having a martensite start temperature of at least about 330°C and consisting of iron and alloying elements comprising about 0.03% to about 0.35% carbon, about 1.0% to about 11.0% chromium, and at most about 2.0% manganese; (b) cooling said starting microstructure under conditions causing conversion thereof to an intermediate microstructure of austenite, ferrite, and carbides, said intermediate microstructure comprising contiguous phases of austenite and ferrite with carbide precipitates dispersed in said ferrite phases and substantially no carbide precipitates a{phase boundaries; and (c) cooling said intermediate microstructure under conditions causing conversion thereof to a final microstructure of martensite, austenite, ferrite, and carbides, said final microstructure comprising martensite-austenite regions consisting of laths of martensite alternating with thin films of austenite, ferrite regions contiguous with said martensite-austenite regions, and carbide precipitates dispersed in said ferrite regions, with substantially no carbide precipitates at interfaces between said martensite laths and said austenite thin films, or at interfaces between said ferrite regions and said martensite-austenite regions.
Patent NZ-556219-A (NZ)
Title: Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
Inventor: CHU ZHI-LIANG
IPC: A61K31/00
Filed: 2006-01-09
Abstract: Provided are ex vivo methods of identifying GLP-1 secretagogues, comprising determining whether the test compound which stimulates GPR119 receptor also stimulates GLP-1 secretion from mammalian enteroendocrine cells or raises level of GLP-1 in blood. The methods are useful in identifying suitable GPR119 agonists for combining with dipeptidyl peptidase IV inhibitors for lowering blood glucose level.
Patent NZ-567727-A (NZ)
Title: Communicating with business customers
Inventor: MECILATI DIDI AVRAHAM
IPC: G06Q10/00
Filed: 2005-09-28
Abstract: A system for enabling rerouting of communications at a plurality of communications service providers is disclosed. The system comprises means for integrating routing information for customers across physical, analog and digital communication service providers of the customers. At least one of the communication service providers is a physical mail service provider. The system further comprises means for using the integrated routing information to provide rerouting information to the communication service providers. The means for integrating comprises means for providing a business with a unified communications number for all types of customer communication; and means for mapping the unified communications number to each address for the business issued by the communication service providers of the business
Patent NZ-571371-A (NZ)
Title: Safety shield for injection devices having outer sheath movable relative to inner sheath
Inventor: CHELAK TODD M
IPC: A61M5/32
Filed: 2007-03-21
Abstract: A passive latch ring safety shield (10) for use with medical injection devices is disclosed. The safety shield includes an inner sheath (16) defining a channel which is dimensioned to receive an injection device (12) and an outer sheath (14) defining a channel which is dimensioned to slidably receive the inner sheath. A biasing member (80) is provided between the inner and outer sheaths to urge the outer sheath in relation to the inner sheath from a retracted position to an advanced position. A resilient latch ring (20) is supported on the safety shield in a position to prevent movement of the outer sheath in relation to the inner sheath from a retracted to and advanced position. The latch ring is deformable in response to actuation of the injection device to disengage the outer sheath from the inner sheath and allow the biasing member to move the outer sheath from the retracted position to the advanced position in relation to the inner sheath. Preferably, the latch ring is substantially oval in its undeformed condition and substantially circular in its deformed condition.
Patent NZ-577105-A (NZ)
Title: Intraocular drug delivery systems
Inventor: ROBINSON MICHAEL R
IPC: A61F2/14
Filed: 2007-11-09
Abstract: Disclosed herein is a biocompatible, injectable intraocular drug delivery system comprising: (a) a plurality of microspheres with an average diameter between 5 about 8 microns and about 14 microns, and (b) an aqueous vehicle for the microspheres, wherein the microspheres consist essentially of: (1) a therapeutic agent which is an alpha 2 adrenergic agonist, such as a brimonidine, e.g. brimonidine tartrate, and; (2) one or more biodegradable polymers, all of which biodegradable polymers are polylactic acid (PLA) polymers, such as poly(D,L)lactide polymer, and; wherein the drug delivery system has a viscosity at 20°C of between about 15,000 cps and about 100,000 cps which permits the drug delivery system to be injected into an intraocular location through a 24 to 30 gauge syringe needle and the microspheres can release between 0.5 micrograms/day to about 20 micrograms/day of the brimonidine for a period of time between about 10 and about 100 days. Additionally wherein the biocompatible drug delivery system is for use in a method of treating an ocular condition, wherein the method does not result in significant ocular surface hyperemia, and wherein the method comprises injecting the drug delivery system onto an intraocular location through a 20 to 26 gauge syringe needle, or implanting the drug delivery system into an intraocular or intravitreal location, wherein the intraocular location is a sub-Tenon, subconjuctival, suprachoroidal, intrascleral or retrobulbar intraocular location. Additionally wherein the biocompatible drug delivery system is for use in a method for lowering intraocular pressure, the method comprising implanting the drug delivery system into an anterior sub-Tenon's space, thereby lowering intraocular pressure.
Patent NZ-583701-A (NZ)
Title: Molecule production by photosynthetic organisms
Inventor: MENDEZ MICHAEL
IPC: C12N15/74
Filed: 2008-09-10
Abstract: Provided is an isolated vector comprising: (a) a nucleic acid encoding one or more mevalonate (MVA) pathway or non-mevalonate (MEP) polypeptides that produce an isoprenoid with two phosphates; (b) a nucleic acid encoding a specified second enzyme which modifies said isoprenoid with two phosphates, e.g., limonene synthase, cineole synthase, pinene synthase etc.; and (c) a promoter configured for expression of said nucleic acid in a chloroplast of a nonvascular, photosynthetic organism, wherein the vector does not comprise the entire genome of a chloroplast. The isoprenoid with two phosphates can be GPP, IPP, FPP, GGPP or DMAPP. Further provided are corresponding host cells comprising the expression vector and method of producing isoprenoids using the host cells.
Patent NZ-585433-A (NZ)
Title: Combinations of fungicidal azoles and pyrion compounds
Inventor: BOSSELAERS JAN PIETER HENDRIK
IPC: A01N43/40
Filed: 2008-11-27
Abstract: Disclosed is a composition comprising a combination of a fungicidal triazole as component (I) selected from azaconazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, hexaconazole, ipconazole, metconazole, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, and triticonazole; and as component (II) 1-hydroxy-2-pyridinone; whereby the ratio by weight of component (I) to component (II) ranges from 10:1 to 1:10. Also disclosed is a method of controlling microbial growth on wood, wood products and biodegrable materials, which comprises applying an antimicrobially effective amount of said composition to the wood, wood products and biodegrable materials to be treated.
Patent NZ-589991-A (NZ)
Title: Toxin genes from bacillus thuringiensis and methods for their use
Inventor: AGARWAL SHRUTI
IPC: C07K14/325
Filed: 2009-06-25
Abstract: Provided is an isolated nucleic acid molecule encoding a novel Bacillus thuringiensis delta-endotoxin protein. Further provided are transgenic plants with the protein and methods of producing the protein for insect pesticides.
Patent NZ-591750-A (NZ)
Title: Use of acylcyclohexanedione carboxylic acid or salts thereof in combination with acylcyclohexanedione carboxylic acid esters for improving the development of gramineous plants
Inventor: RADEMACHER WILHELM
IPC: A01N37/42
Filed: 2009-09-25
Abstract: The disclosure relates to the use of a combination of acylcyclohexanedione carboxylic acid of formula (I) or salts thereof and acylcyclohexanedione carboxylic acid esters of formula (II), such as prohexadione-Ca (ProCa) and trinexapac-ethyl (TriEt) for improving the development of gramineous plants (Poaceae and grasses). The disclosure also relates to a method for improving the development of gramineous plants in which the plants or plant sections thereof are treated with said combination for the purpose of growth regulation in gramineae, for reducing the growth or length of shoots and/or for promoting the root growth of gramineae, or preventing lodging in cereals, and for increasing the yield and/or the grain quality of cereals.
Patent NZ-592581-A (NZ)
Title: Mobile clothesline with wheels
Inventor: KENNEDY TIMOTHY GRAHAM
IPC: D06F53/02
Filed: 2011-05-02
Abstract: Disclosed is a freestanding mobile clothesline comprising two spaced apart pivotally mounted arms which are pivotable about an axis extending through a mid-portion of each arm. A plurality of lines extend between the two arms and at least one of the lines is offset to one side of the axis. The arms are selectively pivotable about the pivot axis in a first direction and a second direction from an initial position in which the arms are substantially horizontal. Selectively pivoting the arms from the initial position in the first direction positions the at least one line higher than the axis. Selectively pivoting the arms from the initial position in the second direction positions the at least one line lower than the axis.
Patent NZ-593806-A (NZ)
Title: Inhibitors of hcv ns5a
Inventor: LI LEPING
IPC: A61K31/4709
Filed: 2009-12-02
Abstract: 593806 The disclosure relates to heteroaryl alkyne and aryl alkyne compounds of formula X or XIV useful for inhibiting hepatitis C virus (”HCV”) replication, particularly functions of the non-structural 5 A (”NS5A”) protein of HCV.
Patent NZ-593937-A (NZ)
Title: Compositions of protein receptor tyrosine kinase inhibitors
Inventor: WU JAY JIE-QIANG
IPC: A61K31/423
Filed: 2009-12-08
Abstract: 593937 Disclosed is the use of 4-{ [3-(4-cyclohexylpiperazin-1-yI)-6-oxo-6H-anthra[1,9-cd]isoxazoI-5-yl]amino} benzoic acid or N-[(4-{ [3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl]amino} phenyl)sulfonyl]acetamide or a salt, solvate, ester, or prodrug thereof, in the manufacture of a medicament for the treatment in a patient of: (a) a pain selected from the group consisting of: acute pain, chronic pain, inflammatory pain, neuropathic pain, tonic pain, persistent pain, postoperative pain, chemical induced pain, chemotherapy-induced pain, cancer-pain, drug-induced pain, bone pain, pain associated with alcohol-induced hyperalgesia, and a combination thereof, and/or (b) skeletal muscle spasms, convulsive seizures, epilepsy, restenosis, atherosclerosis, psoriasis, thrombosis, burn, posttraumatic stress disorder, cardiac disorder, smoking cessation, inflammation, immune-mediated disorders, and a combination thereof; and/or (c) a cancer selected from the group consisting of: brain, melanoma, multiple myeloma, squamous cell, bladder, gastric, pancreatic, breast, head, neck, esophageal, prostate, colorectal, lung, renal, ovarian, gynecological, thyroid, liver, and certain types of hematological malignancies, and a combination thereof; and/or (d) causalgia, diabetes, collagen vascular disease, trigeminal neuralgia, spinal cord injury, brain stem injury, thalamic pain syndrome, complex regional pain syndrome type I/reflex sympathetic dystrophy, Fabry’s syndrome, small fiber neuropathy, cancer, cancer chemotherapy, chronic alcoholism, stroke, abscess, demyelinating disease, viral infection, AIDS, burn, sunburn, arthritis, colitis, carditis, dermatitis, myositis, neuritis, mucositis, urethritis, cystitis, gastritis, pneumonitis, collagen vascular disease, trauma, maladaptive substance use, substance dependence, alcohol use or abuse, substance use or abuse, drug use or abuse, metastasis, fibromyalgia, irritable bowel syndrome, a temporomandibular disorder, inflammation, immune abnormality, and a combination thereof.
Patent NZ-596322-A (NZ)
Title: Compositions and methods for humanization and optimization of N-glycans in duckweed plants
Inventor: DICKEY LYNN F
IPC: A01H5/00
Filed: 2007-01-17
Abstract: Provided is a duckweed plant or duckweed plant cell or nodule that expresses a recombinant glycoprotein having a substantially homogeneous N-glycosylation profile, wherein at least 90% of the N-glycan species present in the profile are G0 glycans, and wherein said duckweed plant, plant cell, or nodule comprises at least one recombinant nucleotide construct that provides for inhibition of expression of alpha-1,3-fucosyltransferase (FucT) and beta-1,2-xylosyltransferase (Xy1T) in said duckweed plant, plant cell, or nodule by means of sense or antisense suppression to the mRNAs of the genes. The modified plants can be used to produce monoclonal antibodies with an altered N-glycosylation profile.
Patent NZ-598201-A (NZ)
Title: Novel glossing system for paper and paperboard coatings
Inventor: ABUNDIS DAVID
IPC: C09D125/04
Filed: 2010-07-28
Abstract: 598201 Provided is a paper coating or binding formulation, comprising an aqueous emulsion which comprises a copolymer derived from one or more monomers, wherein the copolymer has a glass transition temperature greater than 30°C, and an ultrafine kaolin pigment, wherein at least 55% of the kaolin pigment is less than 0.3 µm. In certain embodiments, this invention is directed to a blend of high T9 latex (substantially non-film forming) and ultrafine kaolin. This invention is also directed to a paper comprising a fiber matrix and a coating or binding composition comprising an aqueous emulsion which comprises a copolymer derived from one or more monomers, wherein the copolymer has a glass transition temperature of greater than 30°C, and an ultrafine kaolin pigment, wherein at least 55% of the kaolin pigment is less than 0.3 µm.
Patent NZ-601976-A (NZ)
Title: Cannula device and method and device for providing a cannula device with an implant
Inventor: SPILGIES HEIKO
IPC: B29C48/06
Filed: 2011-03-09
Abstract: 601976 To provide a cannula device (4) with an implant (3), the cannula device (4) is held at an extrusion die in such a way that the cannula device (4) is in contact with a sealing surface of the extrusion die. A flowable implant material is conveyed through the extrusion die into an implant channel (10) of the cannula device (4). The implant material solidifies in the implant channel, for example by means of cooling.
Patent NZ-603026-A (NZ)
Title: Three-Dimensional Weave-Forming Equipment for Composites
Inventor: SHAN ZHONGDE
IPC: D04C3/00
Filed: 2010-08-16
Abstract: 603026 Disclosed is a three-dimensional weave forming apparatus for composites. The apparatus has a workbench (1); a controllable digital template (2) arranged on the workbench (1), which template can reciprocate along the vertical direction; guiding poles (3), one end of each of which is arranged on the controllable digital template (2); guiding sleeves, which are wound on sleeve spindles and after passing through guiding sleeve tensioning devices, pass through the hollow guiding poles (3) and are evaginated, and then fixed on the controllable digital template (2). The smooth wall of the outer surface of the evaginated guiding sleeves (5) abuts against the outer wall of the guiding poles (3) tightly, and the inner surface of the evaginated guiding sleeves (5) are wound with filaments, so as to realise the longitudinal locking of the part. Spools (7) are arranged on the lateral side of a frame (8), with filaments (9) on the spools (7), after being tensioned by filament tensioning devices (11) on needle holders (10), passing through weaving needles (12). A weaving needle pickup device (13) is arranged on the frame (8), with the pickup device (13) driven by an X-axis motor (14) and a Y-axis motor (15) to fetch weaving needles (12) and then weave along a pre-set path in the plane of X and Y.
Patent NZ-603601-A (NZ)
Title: Photoactivatable oxygen-evolving compositions and methods for teeth whitening
Inventor: PIERGALLINI REMIGIO
IPC: A61Q11/00
Filed: 2011-04-29
Abstract: Disclosed herein is a tooth whitening composition-comprising: an oxidizing agent selected from hydrogen peroxide, carbamide peroxide, peroxy acid, peroxy acetic acid, sodium perborate, alkali metal peroxides, alkali metal percarbonates, alkali metal perborates, and combinations thereof; Eosin Y; and a carbomer. Also disclosed is a method for whitening a tooth in vivo in the gingiya of a patient wherein the method comprises the steps of: applying to at least one tooth a tooth whitening composition comprising: Eosin Y; an oxidizing agent selected from hydrogen peroxide, carbamide peroxide, alkali metal peroxides, alkali metal percarbonates, peroxy acetic acid, and alkali metal perborates; an accelerating agent such as sodium perborate; and a stabilizing agent such as sodium acetate trihydrate, and exposing the tooth whitening composition to actinic light for a period between 5 seconds and 10 minutes.
Patent NZ-606701-A (NZ)
Title: Mutated axetohydroxyacid synthase genes in brassica
Inventor: SCHOPKE CHRISTIAN
IPC: C12Q1/68
Filed: 2008-10-03
Abstract: Disclosed is an isolated nucleic acid encoding a Brassica acetohydroxyacid synthase (AHAS) I protein comprising a tryptophan to leucine substitution at a position corresponding to position 574 of SEQ ID NO: 1. Further disclosed are peptides, expression vectors, plants, seeds comprising said W574L substitution in the Brassica napus Acetolactate synthase 1. Further disclosed are methods of increasing herbicide resistance of a Brassica plant, by using said nucleotide, peptide or expression vector thereof.
Patent NZ-608720-A (NZ)
Title: Macrocyclic proline derived hcv serine protease inhibitors
Inventor: OR YAT SUN
IPC: C07D255/04
Filed: 2011-09-20
Abstract: The present disclosure relates to compounds of Formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present disclosure interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present disclosure further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The disclosure also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present disclosure.
Patent NZ-612449-A (NZ)
Title: Process for the preparation of calcobutrol
Inventor: TRENTMANN WILHELM
IPC: A61K49/10
Filed: 2010-11-02
Abstract: The disclosure relates to a calcium complex of 10-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid (Calcobutrol) prepared by a process comprising the steps: (a) the gadolinium complex of 10-(2,3-dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetic acid (Gadobutrol) is de-complexed with a de-complexing agent, wherein the de-complexing agent is an oxalate ion source or a phosphate ion source and the pH before adding the de-complexing agent is higher than 2, (b) the precipitated gadolinium salt is removed, (c) the free ligand in the solution resulting from step (b) is bound to an acidic ion exchange resin, (d) said resin is eluted with an aqueous alkaline solution, (e) the eluate is treated with acidic ion exchange resin, and (f) the ligand is complexed with Ca2+ ions and crystallised. The disclosure furthermore concerns Calcobutrol with a high level of purity, which is used for the preparation of galenic formulations of Gadobutrol, wherein the calcium complex prevents the release of free gadolinium in the formulation (e.g. by storage for several years, re-complexation with foreign ions from the glass).